SynAct Pharma AB (CHIX:SYNACS) E10: kr-6.52 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:SYNACS SynAct Pharma AB CHIX:SYNACS
9 GF Score
Price kr18.62
! 1 Warning Sign
View Full Analysis

What is SynAct Pharma AB E10?

SynAct Pharma AB CHIX:SYNACS 9 E10 is kr-6.52 as of Jun. 2026. GuruFocus rates CHIX:SYNACS with a GF Score™ of 9/100. The stock has 1 warning sign investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

SynAct Pharma AB's adjusted earnings per share data for the three months ended in Jun. 2026 was kr-0.390. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is kr-6.52 for the trailing ten years ended in Jun. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2026-08-26), SynAct Pharma AB's current stock price is kr18.62. SynAct Pharma AB's E10 for the quarter that ended in Jun. 2026 was kr-6.52. SynAct Pharma AB's Shiller PE Ratio of today is .


SynAct Pharma AB  (CHIX:SYNACs) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


SynAct Pharma AB E10 Related Terms


SynAct Pharma AB E10 Historical Data

* Premium members only.

The historical data trend for SynAct Pharma AB's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SynAct Pharma AB E10 Chart

SynAct Pharma AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

SynAct Pharma AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 -7.31 -6.52

CHIX:SYNACS vs VRTX, REGN, RVMD: E10 Comparison

For the Biotechnology subindustry, SynAct Pharma AB's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SynAct Pharma AB Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SynAct Pharma AB's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where SynAct Pharma AB's Shiller PE Ratio falls into.


CHIX:SYNACS
9GF Score
SynAct Pharma AB CHIX:SYNACS
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

SynAct Pharma AB E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, SynAct Pharma AB's adjusted earnings per share data for the three months ended in Jun. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-0.39/134.6100*134.6100
=-0.390

Current CPI (Jun. 2026) = 134.6100.

SynAct Pharma AB Quarterly Data

per share eps CPI Adj_EPS
201609 -0.161 101.138 -0.214
201612 -0.786 102.022 -1.037
201703 -0.265 102.022 -0.350
201706 -0.326 102.752 -0.427
201709 -0.148 103.279 -0.193
201712 -0.454 103.793 -0.589
201803 -0.247 103.962 -0.320
201806 -0.582 104.875 -0.747
201809 -0.444 105.679 -0.566
201812 -0.384 105.912 -0.488
201903 -0.266 105.886 -0.338
201906 -0.424 106.742 -0.535
201909 -0.207 107.214 -0.260
201912 -0.734 107.766 -0.917
202003 -0.138 106.563 -0.174
202006 -0.513 107.498 -0.642
202009 -0.858 107.635 -1.073
202012 -0.347 108.296 -0.431
202103 -0.454 108.360 -0.564
202106 -0.505 108.928 -0.624
202109 -0.694 110.338 -0.847
202112 -1.001 112.486 -1.198
202203 -0.760 114.825 -0.891
202206 -0.902 118.384 -1.026
202209 -0.832 122.296 -0.916
202212 -1.070 126.365 -1.140
202303 -1.576 127.042 -1.670
202306 -1.358 129.407 -1.413
202309 -0.991 130.224 -1.024
202312 -2.557 131.912 -2.609
202403 -0.694 132.205 -0.707
202406 -0.466 132.716 -0.473
202409 -0.495 132.304 -0.504
202412 -0.440 132.987 -0.445
202503 -0.510 132.825 -0.517
202506 -0.560 133.699 -0.564
202509 -0.670 133.480 -0.676
202512 -0.430 133.390 -0.434
202603 -48.000 133.560 -48.377
202606 -0.390 134.610 -0.390

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of kr-6.52 mean?
SynAct Pharma AB (CHIX:SYNACS) has a E10 of kr-6.52 as of Jun. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on SynAct Pharma AB and its competitors.
Is SynAct Pharma AB's E10 too high?
SynAct Pharma AB's current E10 is kr-6.52. Overall, SynAct Pharma AB has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does SynAct Pharma AB's E10 compare to VRTX and REGN?
SynAct Pharma AB's E10 of kr-6.52 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on SynAct Pharma AB and its competitors. SynAct Pharma AB's current E10 is kr-6.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SynAct Pharma AB stock overvalued right now?
SynAct Pharma AB (CHIX:SYNACS) has a current E10 of kr-6.52. The current E10 is kr-6.52. SynAct Pharma AB's overall GF Score™ is 9/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For SynAct Pharma AB (CHIX:SYNACS), the current E10 is kr-6.52 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

SynAct Pharma AB Business Description

Other Exchanges SYNACT:Sweden8F8:Germany
Address Scheelevagen 2, Lund, SWE, 223 63
SynAct Pharma AB is a clinical-stage biotechnology company focused on resolving inflammation through the selective activation of the melanocortin system. The company has a broad portfolio of oral and injectable selective melanocortin agonists aimed at inducing anti-inflammatory and inflammation-resolution activity to help patients achieve immune balance and overcome inflammation. AP1189, the company's drug candidate, is being evaluated in three Phase 2 clinical programs regarding rheumatoid arthritis, idiopathic membranous glomerulonephritis and virus-induced respiratory failure.
9GF Score

Get the complete analysis for CHIX:SYNACS

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr18.62
Price